654 related articles for article (PubMed ID: 24631334)
1. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
2. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
[TBL] [Abstract][Full Text] [Related]
3. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):885-94. PubMed ID: 25663437
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
5. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
Deissler HL; Rehak M; Busch C; Wolf A
Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
[TBL] [Abstract][Full Text] [Related]
6. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
[TBL] [Abstract][Full Text] [Related]
7. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
Deissler H; Deissler H; Lang S; Lang GE
Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2345-53. PubMed ID: 23760670
[TBL] [Abstract][Full Text] [Related]
9. Transport and fate of aflibercept in VEGF-A
Deissler HL; Sommer K; Lang GK; Lang GE
Exp Eye Res; 2020 Sep; 198():108156. PubMed ID: 32712182
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):535-42. PubMed ID: 19643968
[TBL] [Abstract][Full Text] [Related]
11. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
[TBL] [Abstract][Full Text] [Related]
12. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
13. VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A
Deissler HL; Stutzer JN; Lang GK; Grisanti S; Lang GE; Ranjbar M
Exp Eye Res; 2020 May; 194():108004. PubMed ID: 32184103
[TBL] [Abstract][Full Text] [Related]
14. Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):83-94. PubMed ID: 30367290
[TBL] [Abstract][Full Text] [Related]
15. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
Lang GE; Lang GK; Deissler HL
Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
[TBL] [Abstract][Full Text] [Related]
16. Response to anti-VEGF-A treatment of endothelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Exp Eye Res; 2016 May; 146():128-136. PubMed ID: 26771090
[TBL] [Abstract][Full Text] [Related]
17. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2017 Jan; 154():39-46. PubMed ID: 27836572
[TBL] [Abstract][Full Text] [Related]
18. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
19. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.
Campbell M; Collery R; McEvoy A; Gardiner TA; Stitt AW; Brankin B
Curr Eye Res; 2006 Dec; 31(12):1033-45. PubMed ID: 17169842
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
